Yung Zip Chemical Ind. Co., Ltd. AI Stock Analysis
Yung Zip Chemical Ind. Co., Ltd. (4102) AI Stock Analysis
Yung Zip Chemical Ind. Co., Ltd.
(TPEx:4102)
The score is held down primarily by a sharp deterioration in fundamentals: falling revenue, severe margin compression, a swing to an operating and net loss, and near-complete evaporation of operating cash flow with free cash flow turning negative. A conservatively financed balance sheet, with low debt-to-equity of 0.27 and equity funding most of the asset base, provides a cushion and time for management to stabilize operations. Technicals reinforce caution, with the price below all key moving averages and a negative MACD, though oversold RSI and Stochastic readings hint at potential near-term stabilization. Valuation offers an eye-catching 6.52% dividend yield, but with no meaningful P/E due to losses and negative free cash flow, that payout carries sustainability risk. The investment case hinges on whether the margin squeeze proves cyclical, as the 2022-2024 track record suggests, or structural.
Yung Zip Chemical Ind. Co., Ltd. (4102) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 733.07M
- Dividend Yield
- 6.57%
- Average Volume (3M)
- 24.76K
- Price to Earnings (P/E)
- -895.4
- Beta (1Y)
- 0.31
- Revenue Growth
- 7.67%
- EPS Growth
- 86.29%
- Country
- TW
- Employees
- 181
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - General
Yung Zip Chemical Ind. Co., Ltd. Business Overview & Revenue Model
Company Description
Yung Zip Chemical Ind. Co., Ltd. is a global provider specializing in the manufacture of essential pharmaceutical components. The company supplies active pharmaceutical ingredients (APIs), their intermediate precursors, and various specialty chemical...
Yung Zip Chemical Ind. Co., Ltd. Financial Statement Overview
Summary
Financial results deteriorated sharply in 2025. Revenue fell to NT$474.2 million from NT$583.7 million, gross margin compressed from 30.6% to 19.9%, and the company swung from NT$64.6 million of net income to a NT$14.4 million net loss. Cash generation was the weakest area: operating cash flow collapsed to NT$2.1 million from NT$118.7 million and free cash flow turned negative at -NT$36.6 million, meaning current operations no longer fund reinvestment. The balance sheet is the clear offset — equity funds roughly two-thirds of the NT$924.1 million asset base and debt-to-equity of 0.27 is conservative — though borrowings rose to NT$157.4 million while equity shrank about 11% and ROE flipped to -2.4%. The 2022-2024 record of double-digit net margins and solid cash conversion suggests the weakness may be cyclical, but until cash generation recovers, risk remains tilted to the downside.
Income Statement
31NegativeBalance Sheet
66PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 494.04M | 474.22M | 583.70M | 559.15M | 567.33M | 477.60M |
| Gross Profit | 103.03M | 94.57M | 178.40M | 173.89M | 164.97M | 104.51M |
| EBITDA | 28.54M | 17.00M | 113.72M | 106.58M | 117.16M | 49.84M |
| Net Income | 1.13M | -14.36M | 64.61M | 62.51M | 69.99M | 6.00M |
Balance Sheet | ||||||
| Total Assets | 951.87M | 924.11M | 964.63M | 990.27M | 1.03B | 930.25M |
| Cash, Cash Equivalents and Short-Term Investments | 90.37M | 95.04M | 133.53M | 124.11M | 144.18M | 78.20M |
| Total Debt | 163.78M | 157.41M | 102.89M | 152.29M | 214.29M | 252.59M |
| Total Liabilities | 271.94M | 256.81M | 222.61M | 282.49M | 345.94M | 353.87M |
| Stockholders Equity | 599.16M | 588.26M | 664.37M | 635.58M | 613.57M | 514.11M |
Cash Flow | ||||||
| Free Cash Flow | -2.25M | -36.57M | 80.17M | 69.31M | 66.40M | 46.09M |
| Operating Cash Flow | 20.18M | 2.10M | 118.67M | 96.76M | 92.55M | 73.27M |
| Investing Cash Flow | -23.83M | -41.61M | -25.05M | -17.77M | 16.80M | -35.34M |
| Financing Cash Flow | -11.67M | -439.00K | -86.44M | -97.36M | -44.34M | -13.13M |
Yung Zip Chemical Ind. Co., Ltd. Peers Comparison
Overall Rating
- TW:410244Neutral
TW:417140Underperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4102 | Yung Zip Chemical Ind. Co., Ltd. | 17.50 | -4.95 | -22.05% | |
| TW:4117 | General Biologicals Corp. | 7.80 | -4.70 | -37.60% | |
| TW:4171 | GeneReach Biotechnology Corp. | 15.45 | -6.75 | -30.41% | |
| TW:4724 | Meribank Biotech Co Ltd | 9.25 | -7.90 | -46.06% | |
| TW:4732 | Naturewise Biotech & Medicals Corporation | 14.90 | -5.60 | -27.32% | |
| TW:6493 | TTBIO CORP. | 29.05 | -1.40 | -4.60% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026